<li>candesartan<p>tizanidine increases effects of candesartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>citalopram<p>citalopram will increase the level or effect of tizanidine by  Other (see comment). Use Caution/Monitor. Monitor for increased psychomotor impairment and adverse effects.</p></li><li>clobazam<p>tizanidine, clobazam. Other (see comment). Use Caution/Monitor. 
Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).</p></li><li>deferasirox<p>deferasirox will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>eprosartan<p>tizanidine increases effects of eprosartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>ethinylestradiol<p>ethinylestradiol will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Monitor for tizanidine adverse effects (eg, hypotension or bradycardia)</p></li><li>irbesartan<p>tizanidine increases effects of irbesartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>losartan<p>tizanidine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>lurasidone<p>lurasidone, tizanidine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maraviroc<p>maraviroc, tizanidine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, tizanidine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>obeticholic acid<p>obeticholic acid will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. CYP1A2 substrates that have a narrow therapeutic index should be monitored closely and the dose adjusted accordingly.</p></li><li>olmesartan<p>tizanidine increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>sacubitril/valsartan<p>tizanidine increases effects of sacubitril/valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telmisartan<p>tizanidine increases effects of telmisartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>teriflunomide<p>teriflunomide decreases levels of tizanidine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>valsartan<p>tizanidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>vemurafenib<p>vemurafenib increases levels of tizanidine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Concomitant use of vemurafenib with agents with narrow therapeutic windows is not recommended as vemurafenib may alter their concentrations. If coadministration cannot be avoided, use caution and consider dose reduction of concomitant CYP1A2 substrate drug.</p></li>